Original Publication Date: 1 July, 2015
Publication / Source: Journal of Comparative Effectiveness Research
Authors: Nicole M Engel-Nitz, Yanni Hao, Laura K Becker & Randall Gerdes
Aim: To examine cost and mortality differences in postmenopausal women with HR+/HER2- advanced breast cancer. Methods: Using claims data (2007–2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified. Results: Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents.